Do the Blood Pressure Effects of Nonsteroidal Antiinflammatory Drugs Influence Cardiovascular Morbidity and Mortality?
- First Online:
- 215 Downloads
There are many theories about why selective inhibitors of the second isoform of cyclooxygenase (COX-2) increase cardiovascular risk. Although torcetrapib raises blood pressure and cardiovascular risk, it has been difficult to prove such a link for COX-2 inhibitors in randomized clinical trials. This review shows a significant correlation in placebo-controlled trials between the five agents’ elevations in blood pressures and their rate ratios for cardiovascular events. A larger body of evidence arises from randomized clinical trial comparisons of selective versus nonselective inhibitors of COX-2, but these results are heterogeneous for naproxen versus other traditional agents. The best current trial evidence comes from the centrally adjudicated placebo-controlled trials of celecoxib for colonic polyps: If the blood pressure did not rise at 1 or 3 years after randomization, cardiovascular risk did not significantly increase. Many more data will become available in 2013, after the only prospective clinical trial involving cardiovascular end points is completed.
KeywordsMeta-analysis Celecoxib Rofecoxib Valdecoxib Etoricoxib Parecoxib Lumiracoxib COX-2 inhibitors Incident hypertension Composite cardiovascular end point
Recently published papers of interest have been highlighted as: • Of importance •• Of major importance
- 11.Cannon CP, Curtis SP, FitzGerald GA, et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006, 368:1771–1781.CrossRefPubMedGoogle Scholar
- 12.• Garcia Rodriguez LA, Tacconelli S, Patrignani P: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008, 52:1628–1636. Data from a population-based cohort in Italy showed increased risk of myocardial infarction in users of NSAIDs, especially diclofenac and rofecoxib; the authors proposed a testable model for such compounds that may increase cardiovascular risk. Google Scholar
- 17.•• Chan CC, Reid CM, Aw TJ, et al.: Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009, 27:2332–2341. This update to these authors’ prior meta-analysis on the same topic  is the most comprehensive and up-to-date meta-analysis of currently available data. The authors’ discussion of the challenges in collecting and interpreting these data is especially helpful and important.Google Scholar
- 21.•• Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2107–2122. An excellent recent example of how an “off-target” elevation in blood pressure could have been responsible for an increase in cardiovascular risk when the drug itself was effective in treating dyslipidemia and was intended to reduce cardiovascular risk.Google Scholar
- 22.Dullaart RP, Muller Kobold AC, van Tol A: Torcetrapib and coronary events [letter]. N Engl J Med 2008, 358:1862–1864.Google Scholar
- 30.• Wang J, Mullins CD, Mamdani M, et al.: New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. Ann Pharmacol 2007, 41:937–943. This good example of a typical “comparative effectiveness” study of pharmacy records showed little difference in risk of a new prescription for an antihypertensive agent in people previously treated with celecoxib or a nonselective NSAID.Google Scholar
- 31.Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247–1255.CrossRefPubMedGoogle Scholar
- 32.• Chen LC, Ashcroft DM: Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised clinical trials. Pharmacoepidemiol Drug Saf 2007, 16:762–772. In fixed-effects models, the risk of myocardial infarction was higher for five COX-2 selective agents compared with placebo or nonselective NSAIDs, with rofecoxib having the highest risk, compared with naproxen, and valdecoxib having a lower risk, compared with diclofenac.Google Scholar
- 36.• Ross JS, Madigan D, Hill KP, et al.: Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons from postmarket pharmaceutical safety vigilance. Arch Intern Med 2009, 169:1976–1985. This update of an earlier publication , using all data that were made public after the FDA Advisory Committee Hearings, showed that, in cumulative meta-analyses, the risk of cardiovascular events was significantly higher than placebo well before the conclusion of the APPROVe trial.Google Scholar
- 49.• Becker MC, Wang TH, Wisniewski L, et al.: Rationale, design, and governance of the Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009, 157:606–612. This “definitive” randomized clinical trial should have sufficient statistical power to properly test the hypothesis that cardiovascular risk associated with celecoxib is not inferior to that of ibuprofen or naproxen in arthritis patients. Results are expected in 2013.Google Scholar